Department of General and Bariatric Surgery, Center for Minimal-Invasive Surgery, Krankenhaus Sachsenhausen, Frankfurt am Main, Germany.
Obes Surg. 2009 Jun;19(6):677-83. doi: 10.1007/s11695-009-9820-z. Epub 2009 Mar 17.
The implantation of an intragastric balloon constitutes a short-term effective non-surgical intervention to lose weight. The aim of this study was to evaluate retrospectively the clinical outcome and safety of gastric balloon therapy (GBT) in extremely obese patients.
One hundred and nine super- and super-super-obese patients, 64 males and 45 females, mean age 39.1+/-8.4 years, mean body mass index (BMI) 68.8+/-8.9 kg/m2, who underwent GBT for weight loss, were studied retrospectively. GBT was assessed in massively obese patients concerning tolerance, weight loss, number of comorbidities and complications.
A significant reduction in patients' weight and BMI was evident after GBT. Regarding safety, no major complications occurred. Minor complications at balloon placement and removal occurred in one (0.9%) and three patients (2.8%) respectively. Mean duration of GBT was 177.6+/-56.8 days. After GBT, the mean weight loss was 26.3+/-15.2 kg (p<0.001) and the mean BMI reduction was 8.7+/-5.1 kg/m2 (p<0.001) representing a mean percentage of excess BMI lost (%EBL) of 19.7+/-10.2. The highest BMI loss was observed in patients with BMI>80 kg/m2. A noteworthy improvement of comorbidities in 56.8% of the patients was also noted. Of the 109 patients, 69 received subsequent bariatric surgery. All the procedures were performed laparoscopically. Ten patients, with a mean BMI of 68.6+/-10.6 kg/m2 after the removal of the first BIB, received a second BIB resulting in a non-significant weight and BMI loss of 6.3+/-9.4 kg and 1.8+/-2.9 kg/m2, respectively.
Our study indicates the safety and efficacy of GBT in extremely obese patients particularly as a first step before a definitive anti-obesity operation. GBT appears to be a safe, tolerable, and potentially effective procedure for the initial treatment of morbid obesity.
胃内球囊植入术是一种短期有效的非手术减肥干预措施。本研究旨在回顾性评估胃内球囊治疗（GBT）在极度肥胖患者中的临床疗效和安全性。
我们回顾性研究了 109 例超级肥胖和超级超级肥胖患者（64 名男性和 45 名女性），平均年龄 39.1±8.4 岁，平均体重指数（BMI）68.8±8.9kg/m2，这些患者接受 GBT 减肥。我们评估了 GBT 在肥胖患者中的耐受性、体重减轻、并发症和合并症的数量。
GBT 后患者体重和 BMI 明显下降。关于安全性，没有发生重大并发症。在球囊放置和取出时分别有 1 例（0.9%）和 3 例（2.8%）发生轻微并发症。GBT 的平均持续时间为 177.6±56.8 天。GBT 后，平均体重减轻 26.3±15.2kg（p<0.001），平均 BMI 降低 8.7±5.1kg/m2（p<0.001），代表平均超重 BMI 减少 19.7±10.2%。BMI>80kg/m2 的患者 BMI 降低最明显。同时还注意到 56.8%的患者合并症显著改善。在 109 例患者中，69 例接受了后续减重手术。所有手术均经腹腔镜完成。10 例患者在第一个 BIB 取出后 BMI 平均为 68.6±10.6kg/m2，再次接受第二个 BIB，体重和 BMI 分别减轻 6.3±9.4kg 和 1.8±2.9kg/m2，但差异无统计学意义。
我们的研究表明 GBT 在极度肥胖患者中是安全有效的，特别是作为减肥手术的第一步。GBT 似乎是一种安全、耐受且潜在有效的治疗方法，适用于治疗病态肥胖的初始阶段。
